The DEEP project has received research funding from the European Union under the 7th Framework Programme
DEEP-3 is a long-term observational safety study which evaluates the nature and incidence of adverse effects of deferiprone (DFP) in children and adolescents with beta-thalassaemia major and currently involves 18 recruiting centres from 7 different countries: Albania, Cyprus, Greece, Egypt, Italia, Morocco and Tunisia.
On […]
Another step forward has been made toward the enrollment of new patients, which is allowed by the end of October 2015.
Principal Investigators (PIs) are still working to continue the enrollment of patients within the DEEP-2 study and to date a total of 117 patients have been […]
Six key opinion leaders have been interviewed during the Open Meeting and have shared with us their points of view and their direct experiences in contributing in the DEEP study as well as working in a European context.
The interviews offer an interesting picture of what the clinical […]
The first two groups of paediatric patients enrolled at the DEEP-2 Albanian experimental site in Tirana (University Hospital Centre “Mother Teresa”) has performed the MRI scans as per DEEP-2 Study Protocol. Children have been accompanied by the Trial Medical Staff to Athens, where the radiology is […]
